List of Excipients in Branded Drug IPRATROPIUM BROMIDE INHALATION

« Back to Dashboard

Generic Drugs Containing IPRATROPIUM BROMIDE INHALATION

Company	Ingredient	NDC	Excipient
Armstrong Pharmaceuticals Inc	ipratropium bromide inhalation	17270-0401	1,1,1,2-TETRACHLOROETHANE
Armstrong Pharmaceuticals Inc	ipratropium bromide inhalation	17270-0401	ANHYDROUS CITRIC ACID
Armstrong Pharmaceuticals Inc	ipratropium bromide inhalation	17270-0401	DEHYDRATED ALCOHOL

What are the Most Frequently-Used Excipients in IPRATROPIUM BROMIDE INHALATION?

# Of NDCs	Excipient
1	1,1,1,2-TETRACHLOROETHANE
1	ANHYDROUS CITRIC ACID
1	DEHYDRATED ALCOHOL

Ipratropium Bromide Inhalation Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 28, 2026

Ipratropium bromide inhalation is a mature small-molecule market with limited active-ingredient exclusivity and meaningful differentiation potential in formulation, device compatibility, preservative systems, dose uniformity, and patient usability. The strongest commercial opportunities are generic metered-dose inhalers, preservative-free nebulizer solutions, soft-mist inhalers, pediatric presentations, and combination products with albuterol or other bronchodilators.

The main technical choice is the delivery platform:

Platform	Typical excipient strategy	Commercial opportunity	Principal risk
HFA metered-dose inhaler	HFA-134a propellant and ethanol	Generic replacement for Atrovent HFA; lower-cost inhaler	Device, valve, suspension or solution performance
Nebulizer solution	Water, sodium chloride, pH adjuster; optional preservative	Unit-dose and multidose products	Microbial control, stability, ampoule compatibility
Soft-mist inhaler	Aqueous solution with pH and tonicity adjustment	Device-led differentiation and lifecycle management	Device development and combination-product regulation
Dry-powder inhaler	Carrier-based powder, commonly lactose-based	Potential low-propellant platform	Ipratropium dose, powder dispersibility, device resistance
Combination inhaler	Ipratropium with albuterol or another bronchodilator	Established clinical demand and adherence benefits	Compatibility, dose ratio, patent and regulatory complexity

What is the FDA and commercial status of ipratropium bromide inhalation?

Ipratropium bromide is an inhaled anticholinergic bronchodilator approved for chronic obstructive pulmonary disease and related bronchospastic conditions. It is a quaternary ammonium derivative of atropine with low systemic absorption when administered by inhalation.

The principal U.S. reference products include:

Product	Active ingredient	Delivery system	Sponsor or originator	FDA milestone
Atrovent HFA	Ipratropium bromide	HFA metered-dose inhaler	Boehringer Ingelheim	Approved in 2004
Atrovent inhalation solution	Ipratropium bromide	Nebulizer solution	Boehringer Ingelheim and successor product sponsors	Legacy inhalation-solution platform
Combivent	Ipratropium bromide and albuterol sulfate	Metered-dose inhaler	Boehringer Ingelheim	Earlier combination product
Combivent Respimat	Ipratropium bromide and albuterol sulfate	Soft-mist inhaler	Boehringer Ingelheim	Approved in 2011
Generic ipratropium products	Ipratropium bromide	Nebulizer solution and inhaler formats	Multiple ANDA sponsors	Approved through abbreviated pathways

The reference product’s commercial position has weakened because the active ingredient is old, multiple generic products exist, and regulatory exclusivity has expired for the established presentations. FDA labeling identifies HFA-134a and dehydrated alcohol as inactive ingredients in Atrovent HFA. Nebulizer products generally use aqueous systems with sodium chloride, purified water, and pH adjustment, with preservative systems varying by product. [1-4]

What excipients are used in ipratropium bromide inhalation products?

Excipient selection depends on whether the product is a propellant-based aerosol, aqueous nebulizer solution, soft-mist inhaler, or dry powder.

HFA metered-dose inhalers

Atrovent HFA uses:

• Ipratropium bromide monohydrate
• HFA-134a propellant
• Dehydrated alcohol

The formulation is a solution aerosol rather than a conventional suspended drug product. Ethanol functions as a cosolvent and influences solubility, spray characteristics, evaporation rate, valve behavior, and delivered-dose uniformity. HFA-134a provides the propulsive force and has a material impact on pressure, plume geometry, and canister performance. [1]

The main development variables are:

• Ethanol concentration
• Water content
• Drug concentration
• Canister and valve materials
• Actuator orifice geometry
• Priming and repriming behavior
• Delivered-dose uniformity over canister life
• Particle-size distribution and fine-particle dose
• Extractables and leachables
• Temperature-dependent spray performance

A generic sponsor cannot rely on qualitative sameness alone. The formulation and device must produce comparable aerodynamic performance and dose delivery under the applicable FDA product-specific guidance and abbreviated new drug application requirements.

Nebulizer solutions

Ipratropium bromide inhalation solutions commonly use:

• Purified water
• Sodium chloride for isotonicity
• Hydrochloric acid or another pH adjuster
• Optional antimicrobial preservative

Aqueous solutions are technically simpler than HFA inhalers but have different risks. The formulation must control pH, osmolality, assay, impurities, microbial quality, and compatibility with jet, ultrasonic, or vibrating-mesh nebulizers.

Preservatives can lower manufacturing and multidose-packaging costs but may create tolerability, labeling, and market-positioning disadvantages. Benzalkonium chloride, for example, is used in some inhaled products but can raise concerns relating to bronchospasm or repeated exposure in susceptible patients. Preservative-free unit-dose packaging has a stronger clinical and commercial position in hospital, pediatric, and chronic-use settings.

Soft-mist inhalers

A soft-mist product generally uses an aqueous solution rather than a propellant. The formulation must support:

• Stable drug concentration
• Controlled pH
• Appropriate osmolality
• Low particulate burden
• Long-term device compatibility
• Consistent spray formation
• Acceptable plume duration
• Low delivered-dose variability

The device creates the aerosol through mechanical energy and nozzle geometry. The excipient burden is lower than in many propellant products, but the device is more central to product performance. A successful soft-mist formulation can create a differentiated product even when active-ingredient patent protection is absent.

Dry-powder inhalers

A dry-powder formulation could use a carrier such as lactose, although the feasibility of this approach depends on the target dose and required aerodynamic performance. Ipratropium bromide is administered at a relatively low inhaled dose, which may require carrier engineering, ordered mixtures, spray drying, or carrier-free particle design.

The principal technical risks are:

• Moisture sensitivity
• Cohesion and agglomeration
• Low-dose content uniformity
• Device resistance
• Patient inspiratory-flow dependence
• Powder retention in the device
• Stability after repeated opening

Dry-powder delivery could support a propellant-free product, but the development burden is higher than for a conventional nebulizer solution.

What patents protect ipratropium bromide inhalation products?

The core ipratropium bromide composition is mature and does not provide a practical new chemical entity exclusivity position. Commercial protection has historically depended on product-specific formulations, inhaler devices, manufacturing processes, combination products, and method-of-use claims.

The relevant patent categories are:

Patent category	Potential claim scope	Commercial relevance
Formulation patents	Solvent, propellant, pH, tonicity, preservative, concentration	Can delay or complicate formulation copying
Device patents	Valve, actuator, nozzle, dose counter, soft-mist mechanism	Important for inhaler substitution
Combination patents	Ipratropium plus albuterol or another active	Relevant to Combivent-type products
Method-of-use patents	COPD, bronchospasm, dosing schedules, patient subgroups	Usually narrower than product protection
Manufacturing patents	Filling, crimping, sterilization, particle engineering	Can create process barriers
Packaging patents	Unit-dose ampoules, containers, moisture barriers	Relevant to stability and preservative-free products

Current U.S. Orange Book status must be assessed by reference product and dosage form. A patent listed against a combination product does not automatically block an ipratropium-only product. Likewise, a device patent may affect an inhaler presentation without preventing approval of an alternative device.

For mature ipratropium products, the practical patent question is usually not whether the active ingredient is protected. It is whether a proposed product would infringe an unexpired formulation, device, combination, or manufacturing claim.

When does ipratropium bromide lose exclusivity?

Ipratropium bromide has already lost active-ingredient exclusivity in the United States. Atrovent HFA was approved in 2004, and Combivent Respimat was approved in 2011. Those approvals do not create a current NCE barrier for new ipratropium products.

Exclusivity issue	Current commercial implication
NCE exclusivity	Expired for the mature active ingredient
Orphan exclusivity	Not the principal protection strategy
Pediatric exclusivity	Any historical period does not create a current market barrier
Product-specific exclusivity	Relevant only if tied to a particular later-approved formulation or combination
Patent exclusivity	Must be reviewed by product, dosage form, and jurisdiction
Device protection	Can remain commercially relevant even when drug patents have expired

Generic entry therefore depends more on FDA product-specific requirements, manufacturing capacity, device availability, and litigation strategy than on the original active-ingredient patent estate.

How strong is the patent estate for ipratropium bromide inhalation?

The patent estate is generally weak for the active ingredient and stronger for complex delivery systems.

Stronger protection areas

• Proprietary soft-mist inhaler mechanisms
• Drug-device combinations with integrated dose counting
• Specific aerosol valve and actuator configurations
• Narrow combination-product formulations
• Particle-engineered dry powders
• Stability-enhancing packaging systems
• Manufacturing processes that materially affect aerosol performance

Weaker protection areas

• Basic ipratropium bromide aqueous solutions
• Sodium chloride isotonicity systems
• Conventional pH-adjusted nebulizer formulations
• Generic unit-dose packaging
• Broad method-of-use claims covering established COPD treatment

Patent strength should be evaluated using claim breadth, remaining patent term, prosecution history, obviousness risk, enablement, written-description support, and design-around options. A narrow device claim may have commercial value only if the device is difficult to replace without losing dose performance or patient usability.

What Paragraph IV challenges and litigation affect ipratropium bromide?

Paragraph IV risk is product-specific. An ANDA sponsor may certify that a listed patent is invalid, unenforceable, or not infringed. For legacy ipratropium products, the highest litigation exposure historically has been associated with inhaler devices, combination products, and later-generation delivery platforms rather than the active ingredient itself.

The principal litigation scenarios are:

1. An ANDA sponsor files a Paragraph IV certification against a listed formulation or device patent.
2. The reference sponsor files an infringement action within 45 days.
3. FDA approval may be subject to a statutory stay, generally up to 30 months, unless the case is resolved earlier.
4. The ANDA sponsor may launch at risk before final resolution.
5. A settlement may provide a licensed entry date, authorized generic arrangement, or other market-access terms.

No biosimilar pathway applies. Ipratropium bromide is a chemically synthesized small molecule, so competitive entry occurs through ANDAs, 505(b)(2) applications, or full applications rather than biosimilar applications.

A diligence review should separate:

• Ipratropium-only products
• Ipratropium-albuterol combinations
• Atrovent HFA-related products
• Combivent Respimat-related products
• Nebulizer solutions
• Device patents not listed in the Orange Book
• Patent claims asserted in district court but not listed against the reference product

What commercial opportunities exist for ipratropium bromide excipients?

Preservative-free nebulizer solutions

Preservative-free unit-dose products are the clearest formulation opportunity. A sponsor can differentiate through:

• Low extractables plastic ampoules
• Improved weld integrity
• Long shelf life
• Reduced residual volume
• Compatibility with multiple nebulizer types
• Hospital-friendly packaging
• Barcoded unit-dose cartons
• Pediatric and geriatric labeling support

The formulation itself may be straightforward, but manufacturing controls and packaging performance can create a durable commercial advantage.

HFA inhaler cost reduction

A generic HFA product can compete through:

• Lower ethanol consumption
• Reduced fill weight
• Lower-cost canisters
• Alternative valves
• Simplified actuator architecture
• Improved canister utilization
• Contract manufacturing scale

The commercial challenge is achieving equivalent aerosol performance while preserving reliable dose delivery through the final labeled actuation.

Soft-mist lifecycle products

Soft-mist delivery can support premium pricing if it improves coordination, inspiratory-flow requirements, or portability. The opportunity is strongest for patients who have difficulty using conventional pressurized metered-dose inhalers or who prefer a propellant-free product.

The main barrier is the cost and complexity of the device platform. This is more attractive as a combination product or respiratory portfolio platform than as a standalone ipratropium product.

Combination products

Ipratropium-albuterol remains commercially important because the two actives address complementary bronchodilator mechanisms. Excipient and device opportunities include:

• Single-device administration
• Improved dose synchronization
• Lower actuator force
• Reduced residual volume
• Preservative-free aqueous delivery
• Soft-mist combination delivery
• Digital dose tracking

Combination products carry greater regulatory and patent complexity but can command stronger commercial positioning than ipratropium monotherapy.

Pediatric and geriatric products

Commercial differentiation can focus on:

• Lower actuation force
• Easier priming
• Spacer compatibility
• Clear dose counters
• Reduced mouthpiece resistance
• Unit-dose labeling
• Simplified instructions
• Reduced dependence on hand-breath coordination

These features may be protected through device or design patents and can support non-price competition in a mature generic market.

How does ipratropium compare with competing inhaled bronchodilators?

Product class	Typical role	Excipient and device opportunity	Competitive position
Ipratropium	Short-acting anticholinergic	Preservative-free solution, HFA, soft mist	Mature, price-sensitive
Albuterol	Short-acting beta agonist	HFA, dry powder, nebulizer, digital device	Larger generic market
Ipratropium-albuterol	Dual short-acting bronchodilator	Combination aerosol or soft mist	Stronger differentiation
Tiotropium	Long-acting anticholinergic	Capsule DPI or soft-mist systems	Higher-value maintenance market
Glycopyrrolate	Long-acting anticholinergic	DPI, nebulized or metered systems	Newer competitive positioning

Ipratropium has lower standalone pricing power than long-acting anticholinergics. Its commercial value increases when paired with albuterol, integrated into a differentiated device, or supplied through institutional channels requiring reliable unit-dose availability.

What geographic opportunities exist for ipratropium bromide inhalation?

The United States is a mature generic market. Growth opportunities may be stronger in countries where:

• Nebulizer access is expanding
• COPD diagnosis is increasing
• Local manufacturing is favored
• Hospital procurement is fragmented
• Preservative-free products are underrepresented
• HFA transition has created supply gaps
• Soft-mist devices have limited competition

Regulatory requirements differ by region. European and other international markets may require device comparability, human-factor evidence, or locally specific inhalation-performance testing. Patent status must be reviewed separately in each jurisdiction because U.S. expiration or noninfringement does not determine international freedom to operate.

What manufacturing and IP barriers affect market entry?

The principal manufacturing barriers are:

• High-precision metering valves
• Aerosol filling and crimping equipment
• Control of ethanol and water content
• Canister and elastomer compatibility
• Aerosol particle-size testing
• Sterile or controlled microbial manufacture for nebulizer solutions
• Low-dose content uniformity
• Device assembly and human-factors validation

For HFA inhalers, the critical capital investment is the filling and valve-assembly line. For nebulizer solutions, the key barriers are sterile processing, container closure integrity, and scalable unit-dose packaging. For soft-mist products, the device supply chain and nozzle manufacturing are the dominant constraints.

Licensing opportunities include:

• Contract access to inhaler platforms
• Device technology licenses
• Regional commercialization rights
• Combination-product development partnerships
• Authorized generic arrangements
• Co-development of preservative-free hospital products

What generic launch scenarios exist for ipratropium bromide?

Low-cost nebulizer launch

This is the lowest technical-risk strategy. The product uses a conventional aqueous formulation and unit-dose packaging. Success depends on manufacturing cost, hospital contracting, supply reliability, and preservative-free positioning.

HFA inhaler launch

This strategy offers greater revenue potential but requires validated device and aerosol performance. The commercial case improves if the sponsor can secure reliable valve supply and achieve a differentiated price without compromising dose uniformity.

Combination-product launch

An ipratropium-albuterol product has a larger addressable market than monotherapy but faces more demanding regulatory, formulation, and device requirements.

Premium soft-mist launch

This is the highest-risk and potentially highest-value strategy. The product requires a proprietary or licensed device and a clinical or usability rationale strong enough to support pricing above conventional generics.

Key Takeaways

• Ipratropium bromide has no meaningful current NCE exclusivity barrier in the United States.
• The active ingredient is weakly protectable; devices, formulations, combinations, and manufacturing methods provide the main IP opportunities.
• Preservative-free nebulizer solutions offer the lowest-risk formulation opportunity.
• HFA inhalers require substantial device, valve, aerosol-performance, and manufacturing control.
• Soft-mist products offer the strongest lifecycle-management opportunity but require greater investment.
• Ipratropium-albuterol combinations generally have better commercial positioning than ipratropium monotherapy.
• No biosimilar pathway applies because ipratropium bromide is a small-molecule drug.
• Paragraph IV exposure depends on the specific reference product and unexpired listed patents.
• Commercial success is likely to depend more on supply reliability, device usability, packaging, and institutional contracting than on active-ingredient patent protection.

FAQs

Is ipratropium bromide inhalation eligible for an ANDA?

Yes. Chemically equivalent ipratropium bromide products can generally use the ANDA pathway when the proposed dosage form, route, strength, labeling, and product performance meet FDA requirements.

Which excipient offers the greatest differentiation opportunity?

The highest differentiation potential lies in the complete formulation-device system rather than a single excipient. In practice, preservative-free aqueous packaging and soft-mist delivery offer stronger commercial differentiation than routine sodium chloride or pH adjustment.

Can benzalkonium chloride be used in ipratropium nebulizer solutions?

It can be used in some inhaled formulations, but the decision requires assessment of tolerability, microbial protection, labeling, repeated-use exposure, and compatibility with the intended patient population.

Is a dry-powder ipratropium product commercially attractive?

It may be attractive as a propellant-free platform, but low-dose content uniformity, powder dispersion, inspiratory-flow dependence, and device performance create higher development risk than a conventional nebulizer solution.

Are Atrovent and Combivent protected by the same patents?

No. Atrovent products contain ipratropium alone, while Combivent products combine ipratropium with albuterol and may use different formulations, devices, patents, and regulatory protections.

References

1. U.S. Food and Drug Administration. (2004). Atrovent HFA (ipratropium bromide) inhalation aerosol prescribing information.

2. U.S. Food and Drug Administration. (2011). Combivent Respimat (ipratropium bromide and albuterol) inhalation spray prescribing information.

3. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. DailyMed. (2024). Ipratropium bromide inhalation solution and inhalation aerosol labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

5. U.S. Food and Drug Administration. (1999). Metered dose inhaler and dry powder inhaler drug products: Chemistry, manufacturing, and controls documentation. FDA guidance.

6. U.S. Food and Drug Administration. (2013). Bioequivalence recommendations for ipratropium bromide inhalation aerosol and inhalation solution products. FDA product-specific guidance.